ZA200508389B - Humanized antibodies to interferon alpha receptor-1(IFNAR-1) - Google Patents

Humanized antibodies to interferon alpha receptor-1(IFNAR-1)

Info

Publication number: ZA200508389B
Authority: ZA; South Africa
Prior art keywords: ifnar; humanized antibodies; interferon alpha; alpha receptor; humanized
Prior art date: 2003-04-23

Application number

ZA200508389A

Other languages

English (en)

Inventor

Josephine M Cardarelli

Chen Tseng-Hui Timothy

King David

Christopher R Bebbington

Pogue Sarah Lee

Francis J Carr

Williams Stephen

Original Assignee

Medarec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-23

Filing date

2005-10-17

Publication date

2006-10-25

2005-10-17 Application filed by Medarec Inc filed Critical Medarec Inc

2006-10-25 Publication of ZA200508389B publication Critical patent/ZA200508389B/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200508389A 2003-04-23 2005-10-17 Humanized antibodies to interferon alpha receptor-1(IFNAR-1) ZA200508389B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46505803P	2003-04-23	2003-04-23

Publications (1)

Publication Number	Publication Date
ZA200508389B true ZA200508389B (en)	2006-10-25

Family

ID=33310989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200508389A ZA200508389B (en)	2003-04-23	2005-10-17	Humanized antibodies to interferon alpha receptor-1(IFNAR-1)

Country Status (14)

Country	Link
US (3)	US7619070B2 (xx)
EP (2)	EP1631590B1 (xx)
JP (3)	JP2007525458A (xx)
KR (2)	KR20080045765A (xx)
CN (1)	CN1795010A (xx)
AT (1)	ATE517920T1 (xx)
AU (1)	AU2004233346B2 (xx)
BR (1)	BRPI0410492A (xx)
CA (1)	CA2523142A1 (xx)
ES (1)	ES2368737T3 (xx)
MX (1)	MXPA05011406A (xx)
NZ (1)	NZ542988A (xx)
WO (1)	WO2004094473A2 (xx)
ZA (1)	ZA200508389B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100536919C (zh)	2001-01-09	2009-09-09	贝勒研究院	干扰素拮抗剂和Flt3L拮抗剂的用途
NZ542866A (en)	2003-04-23	2009-07-31	Medarex Inc	Compositions and methods for the therapy of inflammatory bowel disease
ES2368737T3 (es) *	2003-04-23	2011-11-21	Medarex, Inc.	Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
AU2005258077C1 (en) *	2004-06-21	2012-10-25	E. R. Squibb & Sons, L.L.C.	Interferon alpha receptor 1 antibodies and their uses
AU2011236019B2 (en) *	2004-06-21	2012-12-13	E. R. Squibb & Sons, L.L.C.	Interferon alpha receptor 1 antibodies and their uses
US20060019342A1 (en) *	2004-06-25	2006-01-26	Medimmune, Inc.	Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
CN101155831B (zh)	2005-02-10	2015-08-19	贝勒研究院	抗干扰素α单克隆抗体及其使用方法
US7888481B2 (en)	2005-02-10	2011-02-15	Baylor Research Institute	Anti-interferon alpha monoclonal antibodies and methods for use
GB2429013C (en) *	2005-08-11	2012-11-28	Arpi Matossian-Rogers	Peptides for treatment and diagnosis of autoimmunedisease
CN106086175B (zh) *	2006-04-24	2020-03-03	健泰科生物技术公司	用于检测自身免疫性病症的方法和组合物
JP2007306828A (ja) *	2006-05-17	2007-11-29	Tokai Univ	非還元マンノース残基を認識するファージ提示型単鎖抗体
JP2010530895A (ja) *	2007-06-21	2010-09-16	アンジェリカセラピューティックス，インク．	修飾毒素
WO2009110944A1 (en) *	2008-02-29	2009-09-11	Angelica Therapeutics, Inc.	Modified toxins
NZ591098A (en)	2008-08-20	2012-08-31	Centocor Ortho Biotech Inc	Engineered anti-il-13 antibodies, compositions, methods and uses
GB0817891D0 (en)	2008-09-30	2008-11-05	Medical Res Council	Antibodies against il-25
RS55641B1 (sr)	2009-09-03	2017-06-30	Medimmune Llc	Dijagnostičko sredstvo interferon tipa 1
JP5310878B2 (ja)	2011-02-17	2013-10-09	株式会社ニコン	投射型表示装置、携帯型電子機器およびデジタルカメラ
US9402994B2 (en)	2011-07-14	2016-08-02	Cyberonics, Inc.	Powering of an implantable medical therapy delivery device using far field radiative powering at multiple frequencies
WO2014150600A2 (en)	2013-03-15	2014-09-25	Angelica Therapeutics, Inc.	Modified toxins
TWI713453B (zh) *	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
WO2018010140A1 (zh) *	2016-07-14	2018-01-18	中国科学院生物物理研究所	I型干扰素受体抗体及其用途
EA202190378A1 (ru) *	2018-09-18	2021-09-06	Ай-Маб Биофарма (Ханчжоу) Ко., Лтд.	Антитела против ifnar1 для лечения аутоиммунных заболеваний
CN116333132A (zh) *	2019-01-31	2023-06-27	广东旋玉健康生物科技有限公司	新型抗ifnar1抗体
WO2020165437A1 (en)	2019-02-15	2020-08-20	Astrazeneca Ab	Type i interferon-mediated disorders
CN113521276B (zh) *	2021-07-13	2022-04-12	江苏荃信生物医药股份有限公司	包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US5156840A (en)	1982-03-09	1992-10-20	Cytogen Corporation	Amine-containing porphyrin derivatives
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US5374548A (en)	1986-05-02	1994-12-20	Genentech, Inc.	Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es)	1985-06-26	1992-08-01	Liposome Co Inc	Metodo para acoplamiento de liposomas.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5057313A (en)	1986-02-25	1991-10-15	The Center For Molecular Medicine And Immunology	Diagnostic and therapeutic antibody conjugates
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
IL78444A (en) *	1986-04-08	1992-05-25	Yeda Res & Dev	Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
US5889151A (en) *	1989-10-20	1999-03-30	Societe Leb-Tech	Purified human alpha interferon receptor
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
EP0563487A1 (en) *	1992-03-31	1993-10-06	Laboratoire Europeen De Biotechnologie S.A.	Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
GB9223377D0 (en)	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
AU7782894A (en) *	1993-09-17	1995-04-03	Laboratoire Europeen De Biotechnologie S.A.	Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
US5818453A (en) *	1996-01-05	1998-10-06	Weavexx Corporation	System for evaluating print quality for a sheet
JP2000510692A (ja) *	1996-05-04	2000-08-22	ゼネカリミテッド	Ｃｅａに対するモノクローナル抗体、その抗体を含む結合体、およびａｄｅｐｔシステムにおけるそれらの治療的使用
CA2272842C (en) *	1996-11-27	2012-05-15	Genentech, Inc.	Humanized anti-cd11a antibodies
JP2002512624A (ja) *	1997-05-21	2002-04-23	バイオベーションリミテッド	非免疫原性タンパク質の製造方法
WO2000058362A1 (en) *	1999-03-26	2000-10-05	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
SI1189641T1 (sl) *	1999-06-25	2009-12-31	Genentech Inc	Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2
GB0001712D0 (en) *	2000-01-25	2000-03-15	Pharma Pacific Pty Ltd	Therapeutic peptides
GB0001710D0 (en)	2000-01-25	2000-03-15	Pharma Pacific Pty Ltd	Therapeutic treatment
HU227039B1 (en)	2000-01-25	2010-05-28	Egis Gyogyszergyar Nyilvanosan	New process for the production of quetiapine and intermediates therefor
JP2005512962A (ja) *	2001-09-20	2005-05-12	アレクシオンファーマシューティカルズ，インコーポレイテッド	抗ｐｄｇｆ抗体および設計抗体の産生方法
NZ542866A (en) *	2003-04-23	2009-07-31	Medarex Inc	Compositions and methods for the therapy of inflammatory bowel disease
ES2368737T3 (es) *	2003-04-23	2011-11-21	Medarex, Inc.	Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
US8162912B2 (en)	2008-05-30	2012-04-24	Kimberly Clark Worldwide, Inc.	Personal wear absorbent article with disposal tab

2004
- 2004-04-23 ES ES04750579T patent/ES2368737T3/es not_active Expired - Lifetime
- 2004-04-23 BR BRPI0410492-7A patent/BRPI0410492A/pt not_active IP Right Cessation
- 2004-04-23 EP EP04750579A patent/EP1631590B1/en not_active Expired - Lifetime
- 2004-04-23 NZ NZ542988A patent/NZ542988A/en unknown
- 2004-04-23 US US10/831,459 patent/US7619070B2/en not_active Expired - Fee Related
- 2004-04-23 CA CA002523142A patent/CA2523142A1/en not_active Abandoned
- 2004-04-23 CN CNA2004800141023A patent/CN1795010A/zh active Pending
- 2004-04-23 WO PCT/US2004/012649 patent/WO2004094473A2/en active Application Filing
- 2004-04-23 EP EP10011473A patent/EP2404615A1/en not_active Withdrawn
- 2004-04-23 AU AU2004233346A patent/AU2004233346B2/en not_active Ceased
- 2004-04-23 AT AT04750579T patent/ATE517920T1/de not_active IP Right Cessation
- 2004-04-23 KR KR1020087010204A patent/KR20080045765A/ko not_active Application Discontinuation
- 2004-04-23 JP JP2006513277A patent/JP2007525458A/ja active Pending
- 2004-04-23 KR KR1020057020179A patent/KR100872210B1/ko not_active IP Right Cessation
- 2004-04-23 MX MXPA05011406A patent/MXPA05011406A/es unknown
2005
- 2005-10-17 ZA ZA200508389A patent/ZA200508389B/xx unknown
2009
- 2009-09-28 JP JP2009223533A patent/JP2009298818A/ja active Pending
- 2009-09-29 US US12/569,205 patent/US7888484B2/en not_active Expired - Fee Related
2010
- 2010-11-18 JP JP2010258382A patent/JP2011032292A/ja active Pending
- 2010-12-20 US US12/972,813 patent/US8758757B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MXPA05011406A (es)	2005-12-12
BRPI0410492A (pt)	2006-06-13
US20050208041A1 (en)	2005-09-22
US20100104569A1 (en)	2010-04-29
WO2004094473A2 (en)	2004-11-04
NZ542988A (en)	2008-07-31
CN1795010A (zh)	2006-06-28
ATE517920T1 (de)	2011-08-15
US7619070B2 (en)	2009-11-17
CA2523142A1 (en)	2004-11-04
KR20060011968A (ko)	2006-02-06
EP1631590B1 (en)	2011-07-27
ES2368737T3 (es)	2011-11-21
AU2004233346B2 (en)	2008-03-06
JP2011032292A (ja)	2011-02-17
US20110086422A1 (en)	2011-04-14
KR20080045765A (ko)	2008-05-23
JP2007525458A (ja)	2007-09-06
AU2004233346A1 (en)	2004-11-04
EP2404615A1 (en)	2012-01-11
JP2009298818A (ja)	2009-12-24
US8758757B2 (en)	2014-06-24
US7888484B2 (en)	2011-02-15
EP1631590A2 (en)	2006-03-08
KR100872210B1 (ko)	2008-12-05
WO2004094473A3 (en)	2005-06-02

Publication	Publication Date	Title
ZA200508389B (en)	2006-10-25	Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2005103081A3 (en)	2005-12-01	Human monoclonal antibodies against cd20
MX2007011064A (es)	2008-02-19	Anticuerpos contra cd38 para tratamiento de mieloma multiple.
RS80704A (xx)	2006-12-15	ANTI-αvβ6 ANTITELA
SI1629011T1 (sl)	2010-05-31	Humane molekule za vezavo anti hu cd
WO2007062245A3 (en)	2007-12-06	Human monoclonal antibody human cd134 (ox40) and methods of making and using same
TW200722437A (en)	2007-06-16	Anti-TrkB monoclonal antibodies and uses thereof
WO2009061996A3 (en)	2009-09-03	Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2006089133A3 (en)	2006-12-21	Anti-cd19 antibodies and uses in oncology
TNSN06087A1 (en)	2007-10-03	Therapeutic binding molecules
TW200510459A (en)	2005-03-16	RG1 antibodies and uses thereof
DK1406656T3 (da)	2013-04-15	Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
DE60028970D1 (de)	2006-08-03	An her2 bindende peptidverbindungen
EP4279140A3 (en)	2024-01-31	Human antibodies against tissue factor
EA200801509A1 (ru)	2008-12-30	Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
HK1153649A1 (zh)	2012-04-05	治療性抗單克隆抗體
WO2003055917A3 (en)	2003-12-24	Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
WO2004108766A3 (en)	2005-06-30	Anti-hgf-r antibodies and their use
HK1096103A1 (en)	2007-05-25	Anti-epcam immunoglobulins
WO2003104425A3 (en)	2005-02-17	NEW STABLE ANTI-CD22 ANTIBODIES
DK1411962T3 (da)	2011-04-04	Terapi for pancreacancer med monoklonalt stof
BRPI0415541B8 (pt)	2021-05-25	uso de uma molécula inibidora de angiogênese, composição terapêutica para tratametno de câncer, e uso do anticorpo h33, produzido pelo hibridoma 13h33
EP1434799A4 (en)	2005-10-05	DNA MOLECULES AND RECOMBINANT DNA MOLECULES FOR THE PREPARATION OF HUMANIZED MONOCLONAL ANTIBODIES TO S.MUTANS
WO2008042941A3 (en)	2008-12-11	Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
UA98100C2 (ru)	2012-04-25	Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его